TRML vs. RXST

In the year-to-date period, TRML achieves a -25.54% return, which is significantly higher than RXST's -62.01% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Tourmaline Bio Inc. (TRML) and RxSight, Inc. (RXST). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current TRML Sharpe Ratio is -0.06, which is higher than the RXST Sharpe Ratio of -1.24. The chart below compares the historical Sharpe Ratios of TRML and RXST, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither TRML nor RXST has paid dividends to shareholders.

The maximum TRML drawdown since its inception was -94.97%, which is greater than RXST's maximum drawdown of -79.69%. Use the drawdown chart below to compare losses from any high point for TRML and RXST. For additional features, visit the drawdowns tool.

Tourmaline Bio Inc. (TRML) has a higher volatility of 24.74% compared to RxSight, Inc. (RXST) at 21.28%. This indicates that TRML's price experiences larger fluctuations and is considered to be riskier than RXST based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Tourmaline Bio Inc. and RxSight, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.